Jazz Pharmaceuticals plc’s recently made public that its EVP, Global Head of R&D & CMO Iannone Robert unloaded Company’s shares for reported $0.33 million on Mar 10 ’25. In the deal valued at $138.41 per share,2,403 shares were sold. As a result of this transaction, Iannone Robert now holds 79,621 shares worth roughly $11.16 million.
Then, Carr Patricia sold 1,140 shares, generating $157,103 in total proceeds. Upon selling the shares at $137.81, the SVP, Chief Accounting Officer now owns 7,012 shares.
Before that, Iannone Robert bought 1,767 shares. Jazz Pharmaceuticals plc shares valued at $256,215 were divested by the Officer at a price of $145.00 per share.
UBS upgraded its Jazz Pharmaceuticals plc [JAZZ] rating to a Buy from a a Neutral in a research note published on March 07, 2025; the price target was increased to $179 from $145. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who decreased its forecast for the stock in late February from “an Overweight” to “a Neutral”. Wells Fargo also remained covering JAZZ and has increased its forecast on February 13, 2025 with a “an Overweight” recommendation from previously “an Equal weight” rating. Morgan Stanley revised its rating on December 12, 2024. It rated JAZZ as “an Overweight” which previously was an “an Equal-weight”.
Price Performance Review of JAZZ
On Monday, Jazz Pharmaceuticals plc [NASDAQ:JAZZ] saw its stock jump 1.64% to $140.22. Over the last five days, the stock has gained 2.02%. Jazz Pharmaceuticals plc shares have risen nearly 13.86% since the year began. Nevertheless, the stocks have risen 19.06% over the past one year. While a 52-week high of $148.06 was reached on 02/26/25, a 52-week low of $99.06 was recorded on 01/10/25. SMA at 50 days reached $129.70, while 200 days put it at $117.14.
Levels Of Support And Resistance For JAZZ Stock
The 24-hour chart illustrates a support level at 138.25, which if violated will result in even more drops to 136.27. On the upside, there is a resistance level at 141.57. A further resistance level may holdings at 142.91. The Relative Strength Index (RSI) on the 14-day chart is 59.87, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.09, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 55.71%. Stochastics %K at 29.05% indicates the stock is a holding.
How much short interest is there in Jazz Pharmaceuticals plc?
A steep rise in short interest was recorded in Jazz Pharmaceuticals plc stocks on 2025-02-28, growing by 0.15 million shares to a total of 4.36 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 4.22 million shares. There was a rise of 3.35%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on June 05, 2024 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $169 price target.
